For example, although 72 (61.5%) mutations, including an oncogenic RB1 S249* mutation, were shared between the SMBO-109 PDO and the tumor from which it was derived, ERBB2 amplification was present only in the organoid line but not in the tumor (Fig. 2A, B). Here, ERBB2 is linked to neoplasm.